Liquid Biopsy Competitive Intelligence Tracker
The LB CI Tracker can be used to extract the following insights and intelligence:
- Who are the leading liquid biopsy players in APAC? In the EU? In North America?
- Which liquid biopsy company had most biopharma collaborations in the past year? What was the nature of these partnerships?
- How many liquid biopsy related abstracts were published at ASCO / AACR / ESMO over the past 3 years? Which abstracts were most popular?
- What percent of liquid biopsy offerings in the U.S. are kits vs. send-out services? What is the approximate turnaround time for these offerings?
- How much funding have liquid biopsy companies raised over the past 3 years? Which companies have raised the most?
- & more
- Author: DeciBio Consulting
- Date: May, 2018
- Price: $ 5,000
Liquid biopsies have gained traction as a minimally invasive method to characterize tumor genomes to inform patient care across the treatment continuum. The liquid biopsy “holy grail” is early detection of cancer in asymptomatic patients, having the potential to increase the survival rate in many cancers. Additional applications such as treatment selection & monitoring also have tremendous benefits and can have a huge impact on the continuum of cancer care. Over 100 companies, including both established and emerging players (e.g., Roche, Qiagen, Guardant Health, Freenome, Tempus, ACT Genomics, Grail) are testing the clinical feasibility of the technology, generating considerable interest among stakeholders. Here are a few of those products (note: updated May 2018):
Competitive Intelligence Tracker
The LB CI Tracker is a customizable competitive intelligence tool, which aggregates relevant secondary data to populate a tracking database. The tool helps teams stay on top of the fast-evolving liquid biopsy space across a variety of parameters, including latest research activity (publications, trials, conference abstracts), product activity (including regulatory / reimbursement updates and product technical specifications), and funding activity. The tool consolidates a range of disparate sources of data, enabling the extraction of vital competitive insights.
Home Dashboard | Who is winning and why?
Company Profile – Research Activity | What is company X publishing? How many clinical trials are they conducting? Which conferences are they attending? How influential are they at these conferences?
Company Profile – Funding Activity | What is company X’s total funding? How many investors? What is their funding timeline and breakdown?
Company Profile – Product Activity | Which clinical application(s) do company X’s products target? What is the regulatory and reimbursement status for each of company X’s products?
Company Profile – HR Activity | What does hiring activity look like for company X? Who are recent senior hires? What is the sales to engineering ratio?
Company Profile – Engagement Activity | How influential is company X? What news about company X is trending? How is company X perceived by their customers?
Product Lead | Mika Wang
|Mika leads special projects at DeciBio with over 7 years of combined experience in strategy consulting, startups, and academic research. She specializes in developing scalable analytics products, including DeciBio’s liquid biopsy competitive intelligence tool which tracks over 100 companies in the space. Connect with Mika on LinkedIn.|
Schedule a demo with Mika today!